Canaccord Genuity Released a Comprehensive Research Report on MindMed Complete a with Bullish Buy Rating and Price Target The Leading Psychedelic Drug Development Company Also Submitted an Application to Uplist... read more →
Psychedelics Gained Popularity as a Recreational Substance Once LSD Slipped Out of Labs in the Mid to Late 1960s Where Researchers Had Been Experimenting with it Since its Discovery by... read more →
MindMed Plans to Use the Phase 1 Study to Experiment with Dosing Methods to Better Understand How Humans React to Ayahuasca's Active Ingredient, DMT The Phase 1 Clinical Trials Will... read more →
After Getting Off to a Good Start as a Psychotherapeutic Tool By the Middle of the Last Century, It Looked Like Psychedelics Would Become Part of the Medical Mainstream Then... read more →
MindMed Has Developed New Technology That Could Help Shorten or Stop an Unwanted LSD Trip MindMed's 'LSD Neutralizer' Could Help the Industry Reduce the Stigma and Fear Associated with Psychedelics... read more →
Psychedelics Firm MindMed Raised $24 Million in Pre IPO Round Which Featured Kevin O'Leary and Bruce Linton Now Listed on the NEO, MMED Stock Was Very Active on its First... read more →
